UCB connects Cradle’s AI protein-design platform to antibody discovery
UCB and Cradle will combine AI design with experimental laboratory feedback across selected antibody programs, from hit generation through lead optimization and preclinical readiness.
AT A GLANCE
Key points
- Cradle’s platform will support selected programs from hit generation through preclinical readiness.
- Experimental results will feed program-specific models in a lab-in-the-loop workflow.
- Human expertise and scientific judgment remain part of the process.
What is changing?
UCB and Cradle formed a strategic collaboration to use AI-powered protein design in selected antibody-discovery programs. Cradle’s end-to-end platform will support candidate design from hit generation through lead optimization and preclinical readiness.
In the planned workflow, laboratory results will feed back into program-specific models. This can support redesign across multiple biological and developability properties rather than a single objective. Both companies emphasize that human expertise and scientific judgment will remain central to the process.
The announcement does not identify clinical candidates or report completed performance results. Claims about speed and candidate quality should therefore be read as collaboration goals, not evidence of clinical success.
Explore the original sources
Source date: 4 November 2026.
Published by AI Radar: 5 Nov 2026, 02:10 (Istanbul, UTC+3). Updated: 8 Nov 2026, 12:15.
FOLLOW THE TOPIC
Topics and tags
Share your discovery.
Send this story to a friend.
Reader comments
What do you think about this development? Share your experience or question. Comments are published after editorial approval.
Your name/nickname and comment become public if approved. Read: Privacy notice.
Loading comments…